HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
@article{Barter2007HDLCV, title={HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.}, author={Philip John Barter and Antonio M. Jr. Gotto and John C Larosa and Jaman Maroni and Michael Szarek and Scott M. Grundy and John J. P. Kastelein and Vera A. Bittner and J-C. Fruchart}, journal={The New England journal of medicine}, year={2007}, volume={357 13}, pages={ 1301-10 } }
BACKGROUND
High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. [] Key Method The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter).
767 Citations
High-density lipoprotein levels and risk of cardiovascular events: a review
- BiologyJournal of cardiovascular medicine
- 2012
Although niacin has been demonstrated to reduce the incidence of major cardiovascular events paralleling the regression of atherosclerosis, significant side-effects still limit its use, and available guidelines still do not consider HDL-C levels as a specific target for therapy.
Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions.
- MedicineThe American journal of cardiology
- 2009
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
- MedicineThe American journal of cardiology
- 2009
Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
- MedicineJournal of the American College of Cardiology
- 2008
Should low high-density lipoprotein cholesterol (HDL-C) be treated?
- BiologyBest practice & research. Clinical endocrinology & metabolism
- 2014
Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention
- Medicine, BiologyLipids
- 2012
Despite the established efficacy of statin therapy, the risk of cardiovascular events remains high in many patients. We examined high-density lipoprotein (HDL) subclass distribution profiles among…
Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
- MedicineAtherosclerosis
- 2020
Isolated Low HDL
- Biology, Medicine
- 2011
Combining niacin with statin therapy raises HDL-C more than a statin alone and this combination has been shown to reduce atherosclerosis and cardiovascular events in two small-scale clinical trials.
Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome
- Biology, MedicineWiener klinische Wochenschrift
- 2016
High TG and low HDL-C Levels may contribute to residual cardiovascular risk in patients with well-controlled LDL-C levels; however, non-HDL-CLevels at admission did not seem to be predictive for patients with ACS.
High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
- BiologyDrugs in context
- 2018
The current clinical and scientific evidence pertaining to the significance of HDL functionality over the actual HDL-C concentration in mediating the favorable effects on the cardiovascular system is discussed.
References
SHOWING 1-10 OF 26 REFERENCES
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
- Medicine, BiologyJAMA
- 2007
The findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in HDL-C, although it remains to be determined whether the atherosclerotic regression associated with these changes in lipid levels will translate to meaningful reductions in clinical events and improved clinical outcomes.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
- MedicineThe New England journal of medicine
- 2005
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
- MedicineThe American journal of medicine
- 1977
Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment
- MedicineCirculation
- 1992
Serum triglyceride concentration has prognostic value, both for assessing coronary heart disease risk and in predicting the effect of gemfibrozil treatment, especially when used in combination with HDL-C and LDL-C.
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study
- Medicine, BiologyCirculation
- 2001
Optimal LDL-C values are <100 mg/dL in both women and men, and LDL- C, HDL-C, TG, and Lp(a), without additional apolipoproteins or lipid subfractions, provide substantial CHD prediction, with much higher RR in women than men.
Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study.
- MedicineAtherosclerosis
- 1996
Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population.
- MedicineThe American journal of cardiology
- 2001
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
- MedicineCirculation
- 1989
A consistent inverse relation of high-density lipoprotein cholesterol levels and coronary heart disease event rates was apparent in BRHS as well as in the four American studies.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
- MedicineJAMA
- 1998
Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
- Medicine
- 2000
Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.